Sermorelin* · GRF 1-29*
Researchers seeking this product for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
Sermorelin is a synthetic analogue corresponding to the first 29 amino acids of growth hormone-releasing hormone (GHRH). It has been studied for its ability to stimulate the pituitary to release endogenous growth hormone, making it an important research compound for investigating the GHRH-GH-IGF-1 axis.
Research Benefits
Stimulates endogenous growth hormone release through GHRH receptor signaling
Growth hormone pathway research involving the pituitary, GH, and IGF-1
Sleep and metabolic research involving growth hormone signaling
Body-composition research examining changes associated with GH activity
Well-characterized GHRH analogue with a substantial history of clinical and research investigation
Identified Risks & Side Effects
Injection-site reactions such as redness, pain, or irritation may occur
Headache, flushing, or dizziness can occur in some individuals
Fluid retention and related effects are possible with increased GH signaling
Glucose metabolism may be affected through the GH/IGF-1 pathway
Not currently FDA-approved for general anti-aging or wellness use
Route: Subcutaneous, in clinical and research settings | Frequency: Varies by research protocol | FDA Status: Not currently FDA-approved
Researcher Note
Sermorelin is an established research tool for studying the body’s natural GHRH-GH signaling pathway. Unlike direct administration of growth hormone, sermorelin acts upstream by stimulating the pituitary, making it particularly useful for research examining endogenous growth hormone secretion and downstream IGF-1 activity.
Disclaimer
FDA Status: Not currently FDA-approved
Research Classification: Research use only
Compound Type: Synthetic GHRH analogue
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.